Mitochondrial DNA Mutation
3
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
2 treatments under study, led by Elamipretide
Research Leaders
5 sponsors active, led by Stealth BioTherapeutics Inc.
Related Conditions
Often studied with 10 related conditions
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 3 trials
100.0%
+13.4% vs benchmark
33%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (3)
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine
Multimodal Imaging Based on Pathological and Genomic Characteristics
Research Network
Common Treatments
- Elamipretide1
- Patients Diagnosed As Gastrointestinal Mucosal Lesions1
Active Sponsors
- Stealth BioTherapeutics Inc.1
- Affiliated Hospital to Academy of Military Medical Sciences1
- Astellas Pharma Inc1
- Casimir, LLC1
- Mayo Clinic1
Top Investigators
Mayo Clinic
Beijing 302 Hospital
Related Conditions
- Mitochondrial Myopathies2
- Mitochondrial Diseases2
- Endoscopy1
- Mitochondrial Pathology1
- Chronic Progressive External Ophthalmoplegia With Myopathy1